THBD and COVID-19: Specifically, the median frequencies in healthy controls were 0.120% [0.070; 0.225] for CD1c+ cDC2s, 0.0150% [0.010; 0.025] for CD141+ cDC1s and 0.150% [0.090; 0.270] for CD303+ pDCs (Figure 1, Panel B), while those in in COVID-19 patients were 0.000% [0.000; 0.003] for CD1c+ cDC2s, 0.000% [0.000; 0.004] for CD141+ cDC1s and 0.0270% [0.011; 0.037] for CD303+ pDCs (Figure 1, Panel B).